INTRODUCTION 47
Nonsteroidal anti-inflammatory drugs (NSAIDs), which exert their biological action 48 primarily through inhibition of cyclooxygenase (COX) enzymes, have been a major focus in the 49 field of chemoprevention for more than 25 years. At first, the primary agents investigated were 50 the standard non-selective COX inhibitor NSAIDs, particularly piroxicam (1). Piroxicam was 51 highly effective in preclinical models, but has infrequently been used clinically for the past 20 52
years. Approximately two decades ago, it was shown that two different COX enzymes exist, 53
and were designated COX-1 and COX-2 (2). COX-1 is a constitutively expressed enzyme found 54 in a wide variety of tissues. COX-2 is preferentially expressed in lymphoid cells, but can be 55 readily induced by a wide variety of stimuli in many cell types. Both COX-1 and COX-2 catalyze 56 the oxygenation of arachidonic acid to yield prostaglandin H 2 , which in turn can be acted upon 57 by different synthases to yield a variety of prostaglandins (PGs) or thromboxanes depending on 58 the site of formation. These molecules are widely considered to be pro-inflammatory and the 59 measurement of urinary metabolites of PGs can be used to assess COX activity or inhibition in 60
vivo. 61
Interestingly, COX-2 proved to be a bona fide target for cancer intervention, as it is 62 overexpressed in transformed cells and is increased in various tumor types (3). Specific 63 inhibitors of COX 2 (or coxibs) were synthesized and were shown to be highly effective in pre-64 clinical studies in the prevention of various types of cancer (4-6). Clinical prevention trials of the 65 COX-2 inhibitors demonstrated them to be highly effective against colon adenomas and skin 66 cancer (7-8). However, placebo-controlled trials of rofecoxib against colon adenomas at the 67 standard human dose and celecoxib at doses higher than their standard dose increased the 68 incidence of adverse cardiovascular (CV) events (9-10). Therefore, there have been significant 69 efforts to evaluate agents which might have the efficacy of NSAIDs, but without the gastric 70
In the current study, we sought to evaluate the effect of NSAIDs in the prevention of
Immunohistochemical biomarkers developed in bladder cancers of rats treated 140
short term with naproxen. Individual F-344 female rats were treated with naproxen (400 ppm), 141 celecoxib (250 ppm), aspirin (low dose 300 ppm or high dose 3000 ppm), or control diet. After 7 142 days of feeding, individual rats were placed in metabolic cages overnight and urine was 143 collected into cups surrounded by dry ice. Urine was analyzed for PGE-M using mass 144 spectrometry as previously described (17-18), without knowledge of treatment groups. PGE-M 145 was normalized to urinary creatinine. 146 RNA analysis for liver isolation and amplification. Livers were rapidly obtained from 147 rats administered naproxen (400 ppm), NO-naproxen (560 ppm) or control diet for 7 days and 148 snap frozen in liquid nitrogen. RNA was isolated and processed using methods similar to those 149 described previously (19). In brief, total liver RNA from untreated rats and rats treated with 150 naproxen or NO-naproxen was isolated by Trizol (Invitrogen, Carlsbad, CA) and purified using 151 the RNeasy Mini Kit and RNase-free DNase Set (QIAGEN, Valencia, CA). In vitro transcription-152 based RNA amplification was then performed on the samples and cDNA for each sample was 153 synthesized using a Superscript cDNA Synthesis Kit (Invitrogen) and a T7-(dT) 24 primer: 5'-154 GGCCAGTGAATTGTAATACGACT-CACTATAGGGAGGCGG-(dT)24-3'. The cDNA was 155 cleaned and the biotin-labeled cRNA was transcribed in vitro from cDNA using a BioArray High 156
Yield RNA Transcript Labeling Kit (ENZO Biochem, New York, NY), and purified again using the 157 RNeasy Mini Kit. the basis for statistical testing. Differential expression was determined using the t-test with 165 adjusted p<0.05. Genes meeting the criteria were called positive for differential expression. For 166 the selected genes, expression indexes were transformed across samples to an N (0, 1) 167 distribution using a standard statistical Z-transformation. These values were input to the Gene 168
Cluster program of Eisen (20) and genes clustered using average linkage and correlation 169 dissimilarity. 170
171

RESULTS
172
Results with naproxen and NO-naproxen. We had previously shown that higher 173 doses of naproxen (400 ppm) and NO-naproxen (560 ppm) were effective in preventing the 174 development of urinary bladder cancers in the OH-BBN model (13). In the current studies, we 175 initially examined doses approximately 66% lower (naproxen at 128 ppm and NO-naproxen at 176 183 ppm) (Table 1, Figure 1a -b). We found both agents were effective; resulting in >80% 177 decrease in the development of large palpable cancers (>200 mg combined weight of bladder 178 plus lesions) when agents were initiated 2 weeks after the last dose of OH-BBN. The cutoff of 179 200 mg bladder weight was chosen as this weight serves as a surrogate for palpable lesions 180 (16). Once the tumors are palpable they are all invasive. We examined a lower dose of 181 naproxen (75 ppm), hoping to achieve a dose roughly 50% effective that might be used DFMO 182 to reduce toxicity. Surprisingly, this dose was highly effective when initiated 2 weeks after the 183 last dose of OH-BBN. Finally, we employed this low dose of 75 ppm, as well as 400 ppm, 184 beginning 12 weeks after the last OH-BBN; a time when all OH-BBN treated rats have pre-185 cancerous lesions (hyperplasias and dysplasias), and approximately 70% have microscopic 186 cancers (16). Both doses were still effective when initiated at this later time point (Table 1) . 187
Effects with sulindac and NO-sulindac. The NSAID sulindac and its NO derivative 189 were also examined. Sulindac was tested at 400 ppm, its human HED. Sulindac was effective, 190 reducing the incidence of palpable tumors by 46% (Figure 1c-d and certain stress-related genes and genes related to stimuli (Rad52, Rgs16, Lama5, Tyrp1, 213 reasonable interpretation is that both were mediated by the parent compound naproxen. The 215 other finding is that both agents given at equimolar doses altered the same pathways and the 216 same genes. But more interestingly, they both gave almost the same magnitude of expression 217 differences, indirectly reflecting the reproducibility of the array response. We failed to see 218 significant induction of ARE-inducible genes by either of these elements. 
225
(NO-naproxen) (data not shown). None of these differences were statistically significant. In 226 contrast, strong ARE inducers such as dithiolthione increase levels of GST Pi 40-fold, AKR 3A7 227 20-fold, epoxide hydrolase 4-fold, and quinone reductase 5-fold (19) . Table 1 ). Naproxen at 75 ppm was highly effective (3/30 large tumors), while sulindac at 150 234 ppm, a dose used to parallel the human dose of Meyskens et al (15) , was moderately effective 235 (large tumor incidence:16/30, p>0.1). The effects of combining DFMO with naproxen or 236 sulindac were then evaluated. There were no preventive effects of combining DFMO with 237 naproxen vs. naproxen alone. For sulindac (while there was no difference between sulindac 238 alone and sulindac plus DFMO), the combination was significantly different from control 239 (p<0.05), while sulindac alone was not (Figure 3c-d December 17, 2013; DOI: 10.1158 /1940 Effects of various NSAIDs on PGE-M production. Naïve female F-344 rats at8 weeks 242 of age were treated with naproxen (400 ppm), celecoxib (250 ppm), aspirin low dose (300 ppm) 243 and aspirin high dose (3000 ppm) for a period of 7 days and then overnight urines were 244 collected on dry ice and then stored at -80 o C. Levels of 11-α-hydroxy-9, 15-dioxo-2, 3, 4, 5-245 tetranor-prostane-1, 20-dioic acid (PGE-M, a marker of systemic PGE 2 production) were 246 quantified using mass spectrometry and normalized to urinary creatinine. All four agents 247 decreased PGE-M levels (supplementary Table S1 ). Interestingly, low dose aspirin and low 248 dose celecoxib reduced levels 25-30%, high dose aspirin reduced levels 55% and naproxen 249 reduced levels 70%. We have included in the table certain of our previous data dealing with the 250 efficacy of the agents that showed that celecoxib and naproxen were profoundly effective in 251 preventing bladder tumors (87% and 92% decrease, respectively), while high dose aspirin was 252 relatively effective (62% decrease)and finally low dose aspirin was ineffective (5% decrease). 253
Examination of biomarkers in bladder lesions treated short-term with naproxen. 254
Animals bearing palpable bladder tumors were treated with naproxen for 5 days. We examined 255 the effects of naproxen on Ki-67, Bub1, cdc2, TOPO2, TPX-2 and Bubr, proliferation-related 256 biomarkers. We observed no significant decreases in these proteins as determined by IHC (data 257 not shown). 
effective at the HED (400 ppm), reducing the incidence of large palpable cancers by more than 266 85%. We compared results with that of NO-naproxen, and found similar activity at equivalent 267 doses. In contrast, neither agent showed preventive efficacy in a rat mammary cancer model 268 which is routinely insensitive to NSAIDs (13). We felt the most reasonable interpretation was 269 that although NO-naproxen may release NO, its primary effects were via its NSAID release. In 270 the present studies, we wished to further explore the effects of naproxen and sulindac and their 271 NO analogues, as well as combining the ornithine decarboxylase inhibitor DFMO with the 272
NSAIDs. The NO-NSAIDs, by reducing gastric toxicity, and DFMO plus NSAID combinations, 273 by potentially allowing one to employ lower doses of NSAIDs, may reduce toxicity. 274
Our initial effective dose of naproxen (400 ppm) was equivalent to the human dose. 275
However, we observed that a dose of 75 ppm (more than five-fold lower than the HED) was 276 highly effective in preventing the development of large bladder cancers when initiated either 2 277 weeks or 12 weeks following the last dose of OH-BBN ( Table 1 ). Given that the serum half life 278 (T 1/2 ) of naproxen in a rat is strikingly lower than that in a human (T 1/2 in rat <5 hours; T 1/2 in 279 human >15 hours), the efficacy of this lower dose of naproxen was surprising. Finding that 280 these agents are effective even when administered late agrees with our previous data with an 281 EGFR inhibitor and other NSAIDs; demonstrating that agents can be effective even when 282 microscopic lesions already exists (16). It also supports the view that many of these agents 283 have their effects during the latter stages of tumor progression, which is of importance since 284
Phase III clinical prevention trials will involve a late intervention (22). The question this raises 285
regarding the dosing of naproxen is more problematic. Does the effectiveness of a very low 286 dose of naproxen indicate that you could use a lower dose in humans, or does it reflect species 287 or model idiosyncrasies? Furthermore, employing a lower dose of naproxen in humans, 288 presuming that it might be effective, is the potential cardiovascular effects. Part of the rationale 289 for employing naproxen is the excellent CV profile of the agent. However, this is based on a full 290 HED and has been attributed in part to its strong inhibition of COX-1 for an extended time period 291
Cancer Research. We performed two limited studies to examine mechanistic aspects regarding the efficacy 302 of naproxen. First, we examined the effects of NSAIDs, including naproxen, on urinary levels of 303 PGE-M. This metabolite, which is formed during the catabolism of PGE 2 , can be derived from 304 either COX-1 or COX-2 in various tissues and has been often proposed as a potential biomarker 305 to monitor the efficacy of NSAIDs (17-18). We treated naïve F-344 rats for 7 days with naproxen 306 (400 ppm), celecoxib (250 ppm), high dose aspirin (3000 ppm), low dose aspirin (300 ppm), or 307 no treatment. These agents reduced PGE-M levels compared to controls by 68, 30, 55, and 308 25%, respectively. Our interpretation of the data is that naproxen and high dose aspirin inhibited 309 substantially both COX-1 and COX-2. Celecoxib primarily affects COX-2 while the lower dose of 310 aspirin should primarily decrease COX-1. This would be based both on effects of aspirin on 311 purified COX enzymes and the fact that lower doses of aspirin profoundly inhibit thromboxane 312 production, which is mediated by COX-1 but is not an effective anti-inflammatory compound at 313 this dose. Cancer prevention data for these agents showed that naproxen, celecoxib, high dose 314 aspirin, and low dose aspirin decreased tumor formation by 90, 90, 60, and 10%, respectively 315 (16) . These data are compatible with the hypothesis that inhibition of COX-2 is a primary mechanism of the efficacy of these agents in this model. In a recent study, we examined the 317 effects of NSAIDs on the development of squamous cell skin cancers in UV-exposed mice. In 318 this model, we directly measured COX-2 inhibition by NSAIDs in the target tissue. We found 319 when examining naproxen, NO-naproxen, sulindac, celecoxib, and aspirin (high or low doses) 320 that there was a strong correlation between the ability to inhibit COX-2-mediated activity and 321 efficacy in that model (23). This COX-2 related efficacy in the skin model would appear to agree 322 with the correlations we found between PGE-M levels and efficacy in the bladder model. 323
Our second line of inquiry dealt with short term effects of naproxen treatment of rats with 324 palpable bladder tumors. Since naproxen was highly effective late in the bladder tumor process 325 and prior studies with the EGFR inhibitors, which are also effective late, profoundly altered cell 326 proliferation, we thought this was a reasonable approach (24-25). We did not observe 327 alterations in cell proliferation or in proliferation-related proteins. Thus the proliferation pathway 328 which we have previously shown is highly associated with efficacy of various agents in the 329 breast (26) was unaffected by naproxen despite naproxen's striking efficacy. As we postulated 330 many years back it may be that NSAIDs are working earlier on the progression from 331 microadenocarcinoma to large lesions via angiogenesis (5), in which case examining these later 332 lesions might not be optimal. 333
Although our prevention data with naproxen and NO-naproxen seemed compatible with 334 their effects being driven by the NSAID naproxen, we took a second indirect approach to 335 examine this. We examined the effects of naproxen and NO-naproxen on gene expression in 336 the liver to determine whether both yielded similar array signatures and whether we observed 337 an independent NO signal. Significant levels of NO in cell culture stimulate an antioxidant 338 response. The antioxidant activates transcription at specific DNA sequences, designated the 339 antioxidant response element (ARE) that is associated with induction of a wide variety of genes 340 (27) including heme oxygenase-1 (Ho-1), NAD(P)H:quinine oxidoreductase 1 (Nqo1), and 341
Cancer Research.
on April 2, 2017. © 2013 American Association for cancerpreventionresearch.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. glutamate cysteine ligase (Gcl)(28). Genes that are highly induced in the livers of rats treated 342 with agents that stimulate the ARE pathway include glutathione S-transferase pi, aldo-keto 343 reductase family member 3A7, quinone reductases, and epoxide hydrolase (19) . No significant 344 induction of these genes by either agent was observed. However, these genes were highly 345 induced by known ARE agonists such as 1,2 dithiolthione or the triterpenoids in rat liver (19) . 346
Thus, it would appear that substantial levels of NO were not released in the liver. In contrast, 347 both agents did modulate expression of many of the same genes, as shown in the heat map, 348 and the same pathways including small GTPase-mediated signal transduction, protein transport, 349 humans (15). The dose of DFMO we employed was low compared to the HED and was meant 359 to parallel that of Meyskens et al. used in humans. (15) . The dose of sulindac we employed also 360 paralleled Meyskens' dose while the dose of naproxen (75 ppm) was meant to yield a moderate 361 effect but was in fact highly effective on its own. In the present studies, we found that DFMO 362 minimally affected tumor development at this low dose of 1000 ppm. The suboptimal dose of 363 naproxen was highly effective (63% decrease) while 150 ppm sulindac, although trending in the 364 right direction (33% decrease), did not have statistically significant efficacy. Adding DFMO 365 yielded no improvement in the strong efficacy of naproxen. However, DFMO addition slightly 366 increased the efficacy of sulindac. In fact, sulindac, DFMO, and sulindac plus DFMO yielded 367
Cancer Research. Author Manuscript Published OnlineFirst on December 17, 2013; DOI: 10.1158 /1940 rats treated with administered naproxen (75 ppm), DFMO (1000 ppm), naproxen + 502 DFMO, or no agent beginning 2 weeks after the final OH-BBN administration. C, 503
Final bladder weights of rats administered sulindac (150 ppm), DFMO (1000 ppm), 504 sulindac + DFMO, or no agent beginning 2 weeks after the final OH-BBN 505 administration. D, Percent of rats without large bladder tumors at sacrifice in rats 506 treated with sulindac (150 ppm), DFMO (1000 ppm), sulindac + DFMO, or no agent 507 beginning 2 weeks after the final OH-BBN administration. Superscripts with different 508 letters are statistically significantly different from one another (p<0.05). 509
